RECRUITING

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

Official Title

Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.

Quick Facts

Study Start:2020-09-14
Study Completion:2028-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04588077

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. * Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.
  2. * Those who had previous exposure to hepatitis B.
  3. * Post liver transplant patients.
  4. * Less than 18 years old.

Contacts and Locations

Study Contact

CHAU TO, MD
CONTACT
(714)-400-1331
cto@mdmercy.com
Paul Thuluvath, MD
CONTACT
(410)-332-9308
pthuluv@mdmercy.com

Principal Investigator

Paul Thuluvath, MD
PRINCIPAL_INVESTIGATOR
Mercy Medical Center

Study Locations (Sites)

Mercy Medical Center
Baltimore, Maryland, 21202
United States

Collaborators and Investigators

Sponsor: Mercy Medical Center

  • Paul Thuluvath, MD, PRINCIPAL_INVESTIGATOR, Mercy Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-09-14
Study Completion Date2028-12-01

Study Record Updates

Study Start Date2020-09-14
Study Completion Date2028-12-01

Terms related to this study

Keywords Provided by Researchers

  • hepatitis B vaccine
  • Heplisav-B
  • cirrhosis
  • chronic liver disease
  • 2 dose regimen
  • 3 dose regimen
  • non responder
  • poor responder
  • no response

Additional Relevant MeSH Terms

  • Hepatitis B
  • Cirrhosis, Liver
  • Chronic Liver Disease